- Species ReactivityMouse
- SpecificityDetects mouse VE-Cadherin in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) Cadherin-8, rhCadherin-17, rhN-Cadherin, recombinant mouse (rm) E-Cadherin, or rmP-Cadherin is observed.
- SourceMonoclonal Rat IgG2B Clone # 162709
- PurificationProtein A or G purified from hybridoma culture supernatant
- ImmunogenMouse myeloma cell line NS0-derived recombinant mouse VE-Cadherin
Asp46-Gln592 (Gly67 del, Ile69Asp, Lys70Gln)
Accession # 2208309A - FormulationLyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
- LabelUnconjugated
- Western Blot1 µg/mLRecombinant Mouse VE-Cadherin Fc Chimera (Catalog # 1002-VC)
- Flow Cytometry0.25 µg/106 cellsSee below
- CyTOF-readyReady to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
- ReconstitutionReconstitute at 0.5 mg/mL in sterile PBS.
- ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
- Stability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
- Patel, S.D. et al. (2007) Curr. Opin. Struct. Biol. 13:690.
- Vestweber, D. (2008) Arterioscler. Thromb. Vasc. Biol. 28:223.
- Vincent, P.A. et al. (2004) Am. J. Physiol. Cell. Physiol. 286:C987.
- Cavallaro, U. et al. (2006) Exp. Cell Res. 312:659.
- Breier, G. et al. (1996) Blood 87:630.
- Huber, P. et al. (1996) Genomics 32:21.
- Pokutta, S. and W.I. Weis (2007) Annu. Rev. Cell Dev. Biol. 23:237.
- Crosby, C.V. et al. (2005) Blood 105:2771.
- Gavard, J. and J.S. Gutkind (2006) Nat. Cell Biol. 8:1223.
- Calera, M.R. et al. (2004) Exp. Cell Res. 300:248.
- Hewat, E.A. et al. (2007) J. Mol. Biol. 365:744.
- Rudini, N. et al. (2008) EMBO J. 27:993.
- Kogata, N. et al. (2006) Circ. Res. 98:897.
- Ema, M. et al. (2006) Blood 108:4018.
- Long Name:Vascular Endothelium Cadherin
- Entrez Gene IDs:1003 (Human); 12562 (Mouse)
- Alternate Names:7B4 antigen; 7B4; cadherin 5, type 2 (vascular endothelium); cadherin 5, type 2, VE-cadherin (vascular epithelium); Cadherin-5; CD144 antigen; CD144; CDH5; endothelial-specific cadherin; FLJ17376; Vascular endothelial cadherin; VECadherin; VE-Cadherin
Background:
The cadherin (Ca++-dependent adherence) superfamily is a large group of membrane-associated glycoproteins that engage in homotypic, calcium-dependent, cell-cell adhesion events. The superfamily can be divided into at least five major subfamilies based on molecule gene structure, and/or extracellular (EC) and intracellular domains (1-4). Subfamilies include classical/type I, atypical/type II, and desmosomal-related cadherins (1-3). VE-Cadherin (vascular endothelial cadherin; also cadherin-5 and CD144) is a 125 kDa atypical/type II subfamily cadherin. Its subfamily classification is based principally on its genomic structure, as its physical structure is notably divergent from other type II subfamily members (2, 3). Mouse VE-Cadherin is synthesized as a 784 amino acid (aa) type I transmembrane (TM) preproprotein that contains a 24 aa signal peptide, a 21 aa prosequence, a 554 aa extracellular region (ECR), a 21 aa TM segment, and a 164 aa cytoplasmic domain (5, 6). The ECR contains five Ca++-binding cadherin domains that are approximately 105 aa in length. Cadherin domains are comprised of twobeta ‑sheets that are oriented like bread in a sandwich. Although complex, the N-terminal cadherin domain mediates trans interactions, while the internal domains contribute to cis multimerizations (7). Mouse VE-Cadherin ECR is 92%, 77%, and 73% aa identical to rat, human and porcine VE-Cadherin ECR, respectively. VE-Cadherin is involved in the maintenance of endothelial permeability. In this regard, VE-Cadherin does not initiate new blood vessel formation; it maintains it once formed. Thus, when VE‑Cadherin is downregulated, cells part and permeability increases (8). Notably, VEGF is known to promote vascular leakage, and apparently does so by inducing abeta ‑arrestin-dependent endocytosis of VE-Cadherin (9). Part of this effect may be mediated by VE‑Cadherin itself which is reported to increase the membrane half-life of VEGF R2 (10). VE-Cadherin acts homotypically at sites of zonula adherens. On each expressing cell, it is proposed that VE-Cadherin first forms a trimer, which then dimerizes with a trimeric counterpart in-trans. Alternatively, two cis-dimers could act in-trans to generate homotypic binding (11). In addition to cell adhesion, VE‑Cadherin also is reported to mediate TGF-betareceptor assembly. When clustered, VE‑Cadherin enhances T beta RII/T beta RI assembly into an active receptor complex on endothelial cells (12). VE-Cadherin is expressed on endothelial cells, trophoblast cells, endothelial progenitor cells and embryonic hematopoietic cells (5, 8, 13, 14).
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
暂无品牌分类
